Ventyx Biosciences Q3 net loss narrows to $22.8 mln

Reuters11-07

<a href="https://laohu8.com/S/VTYX">Ventyx Biosciences</a> Q3 net loss narrows to $22.8 mln

Overview

Ventyx Q3 net loss narrows to $22.8 mln from $35.2 mln last year
Company's cash reserves expected to fund operations into at least H2 2026
VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's disease

Outlook

Company expects topline data from VTX2735 study in Q4 2025
Ventyx's cash expected to fund operations into at least H2 2026

Result Drivers

FINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026
Expenses - R&D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mln

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 EPS		-$0.32
Q3 Net Income		-$22.83 mln
Q3 Operating Expenses		$24.87 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Ventyx Biosciences Inc is $12.00, about 25% above its November 5 closing price of $9.00

Press Release: ID:nGNX1WBR9C

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581043923?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-07 05:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581043923","market":"fut","top_or_hot":-1,"title":"Ventyx Biosciences Q3 net loss narrows to $22.8 mln","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VTYX\">Ventyx Biosciences</a> Q3 net loss narrows to $22.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Ventyx Q3 net loss narrows to $22.8 mln from $35.2 mln last year</p></li><li><p>Company's cash reserves expected to fund operations into at least H2 2026</p></li><li><p>VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's disease</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline data from VTX2735 study in Q4 2025</p></li><li><p>Ventyx's cash expected to fund operations into at least H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026</p></li><li><p>Expenses - R&amp;D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.83 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$24.87 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Ventyx Biosciences Inc is $12.00, about 25% above its November 5 closing price of $9.00</p></li></ul><p>Press Release: <span>ID:nGNX1WBR9C</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Ventyx Biosciences Q3 net loss narrows to $22.8 mln</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nVentyx Biosciences Q3 net loss narrows to $22.8 mln\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-07 05:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title><a href=\"https://laohu8.com/S/VTYX\">Ventyx Biosciences</a> Q3 net loss narrows to $22.8 mln</title></head><body><p><span>Overview</span></p><ul><li><p>Ventyx Q3 net loss narrows to $22.8 mln from $35.2 mln last year</p></li><li><p>Company's cash reserves expected to fund operations into at least H2 2026</p></li><li><p>VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's disease</p></li></ul><p><span>Outlook</span></p><ul><li><p>Company expects topline data from VTX2735 study in Q4 2025</p></li><li><p>Ventyx's cash expected to fund operations into at least H2 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>FINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026</p></li><li><p>Expenses - R&amp;D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mln</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-$0.32</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-$22.83 mln</p></td><td></td></tr><tr><td><p>Q3 Operating Expenses</p></td><td></td><td><p>$24.87 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for Ventyx Biosciences Inc is $12.00, about 25% above its November 5 closing price of $9.00</p></li></ul><p>Press Release: <span>ID:nGNX1WBR9C</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI1IL:1","article_id":"2581043923","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581043923","pubTimestamp":1762464816,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Ventyx Biosciences Q3 net loss narrows to $22.8 mlnOverviewVentyx Q3 net loss narrows to $22.8 mln from $35.2 mln last yearCompany's cash reserves expected to fund operations into at least H2 2026VTX3","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","VTYX":"Ventyx Biosciences, Inc."},"translate_title":"Ventyx Biosciences第三季度净亏损收窄至2280万美元","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"VTYX":0.9},"content_text":"Ventyx Biosciences Q3 net loss narrows to $22.8 mlnOverviewVentyx Q3 net loss narrows to $22.8 mln from $35.2 mln last yearCompany's cash reserves expected to fund operations into at least H2 2026VTX3232 shows promising Phase 2 results for cardiovascular and Parkinson's diseaseOutlookCompany expects topline data from VTX2735 study in Q4 2025Ventyx's cash expected to fund operations into at least H2 2026Result DriversFINANCIAL POSITION - Cash reserves of $192.6 mln expected to fund operations into at least H2 2026Expenses - R&D expenses fell to $17.7 mln from $30.6 mln a year ago, while general and administrative costs declined to $7.2 mln from $7.9 mlnKey DetailsMetricBeat/MissActualConsensus EstimateQ3 EPS-$0.32Q3 Net Income-$22.83 mlnQ3 Operating Expenses$24.87 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 7 \"strong buy\" or \"buy\", 2 \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for Ventyx Biosciences Inc is $12.00, about 25% above its November 5 closing price of $9.00Press Release: ID:nGNX1WBR9CFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581043923","isCrawlerRequest":true}